The Dengue Vaccine Dilemma: Balancing the Individual and Population Risks and Benefits

1. Simmons CP, Farrar JJ, Nguyen VV, Wills B (2012) Dengue. N Engl J Med 366: 1423–1432. doi: 10.1056/NEJMra1110265 22494122

2. WHO/TDR (2009) Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control: New Edition. Geneva.

3. Olkowski S, Forshey BM, Morrison AC, Rocha C, Vilcarromero S, et al. (2013) Reduced risk of disease during postsecondary dengue virus infections. J Infect Dis 208: 1026–1033. doi: 10.1093/infdis/jit273 23776195

4. Thomas SJ, Rothman AL (2015) Trials and Tribulations on the Path to Developing a Dengue Vaccine. Am J Prev Med 49: S334–344. doi: 10.1016/j.amepre.2015.09.006 26590433

5. Halstead SB (2016) Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge. Am J Trop Med Hyg 95: 741–745. doi: 10.4269/ajtmh.16-0222 27352870

6. Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, et al. (2014) Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384: 1358–1365. doi: 10.1016/S0140-6736(14)61060-6 25018116

7. Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, et al. (2015) Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 372: 113–123. doi: 10.1056/NEJMoa1411037 25365753

8. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C, Chotpitayasunondh T, et al. (2015) Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. N Engl J Med 373: 1195–1206. doi: 10.1056/NEJMoa1506223 26214039

9. Sanofi Pasteur. Dengue Vaccine Approved in Paraguay to Strengthen Dengue Burden Reduction Efforts in Southern Cone. 2016. http://www.sanofipasteur.com/en/Documents/PDF/PR-locaux/Paraguay_RegistraVacunaContraElDengueSanofiPasteur-ENGLISH_rev15_08_2016.pdf Cited 14 October 2016.

10. WHO (2016) Meeting of the Strategic Advisory Group of Experts on immunization, April 2016—conclusions and recommendations. Wkly Epidemiol Rec 91: 266–284. 27236869

11. Flasche S, Jit M, Rodríguez-Barraquer I, Coudeville L, Recker M, Koelle K, et al. (2016) The long-term safety, public health impact, and cost-effectiveness of routine vaccination with a recombinant, live-attenuated dengue vaccine (Dengvaxia): a model comparison study. PLoS Med 13(11):e1002181 doi: 10.1371/journal.pmed.1002181

12. Ferguson NM, Rodriguez-Barraquer I, Dorigatti I, Mier YT-RL, Laydon DJ, et al. (2016) Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment. Science 353: 1033–1036. doi: 10.1126/science.aaf9590 27701113

13. Pang T (2016) SAGE committee advice on dengue vaccine. Lancet Infect Dis 16: 880–882. doi: 10.1016/S1473-3099(16)30167-0 27477966

14. Wilder-Smith A, Vannice KS, Hombach J, Farrar J, Nolan T (2016) Population Perspectives and World Health Organization Recommendations for CYD-TDV Dengue Vaccine. J Infect Dis. E-pub ahead of print. doi: 10.1093/infdis/jiw341 27496977

15. Aguiar M, Stollenwerk N, Halstead SB (2016) The risks behind Dengvaxia recommendation. Lancet Infect Dis 16: 882–883. doi: 10.1016/S1473-3099(16)30168-2 27477967

16. Halstead SB (2016) Critique of World Health Organization Recommendation of a Dengue Vaccine. J Infect Dis. E-pub ahead of print. doi: 10.1093/infdis/jiw340 27496975

17. Thomas SJ, Nisalak A, Anderson KB, Libraty DH, Kalayanarooj S, et al. (2009) Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance. Am J Trop Med Hyg 81: 825–833. doi: 10.4269/ajtmh.2009.08-0625 19861618

18. Sirivichayakul C, Sabchareon A, Limkittikul K, Yoksan S (2014) Plaque reduction neutralization antibody test does not accurately predict protection against dengue infection in Ratchaburi cohort, Thailand. Virol J 11: 48. doi: 10.1186/1743-422X-11-48 24620925

19. Sanofi Pasteur. World’s First Public Dengue Immunization Program Starts in the Philippines. 2016. http://www.sanofipasteur.com/en/articles/World-s-First-Public-Dengue-Immunization-Program-Starts-in-the-Philippines.aspx Cited 14 October 2016.

20. Sanofi Pasteur. First dengue vaccination program in the Americas starts in Paraná State of Brazil. 2016. http://www.sanofipasteur.com/en/Documents/PDF/PR-locaux/BrazilParanastatelaunchdenguevaccine_multilocalPR_EN.pdf Cited 14 October 2016.

21. Douglas DL, DeRoeck DA, Mahoney RT, Wichmann O (2013) Will dengue vaccines be used in the public sector and if so, how? Findings from an 8-country survey of policymakers and opinion leaders. PLoS Negl Trop Dis 7: e2127. doi: 10.1371/journal.pntd.0002127 23516658

22. Schwartz LM, Halloran ME, Durbin AP, Longini IM Jr. (2015) The dengue vaccine pipeline: Implications for the future of dengue control. Vaccine 33: 3293–3298. doi: 10.1016/j.vaccine.2015.05.010 25989449

23. Sirivichayakul C, Barranco-Santana EA, Esquilin-Rivera I, Oh HM, Raanan M, et al. (2016) Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study. J Infect Dis 213: 1562–1572. doi: 10.1093/infdis/jiv762 26704612

24. ClinicalTrials.gov Identifier: NCT02747927 https://clinicaltrials.gov/ct2/show/NCT02747927 Cited 14 October 2016.

25. Kirkpatrick BD, Durbin AP, Pierce KK, Carmolli MP, Tibery CM, et al. (2015) Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults. J Infect Dis 212: 702–710. doi: 10.1093/infdis/jiv082 25801652

26. ClinicalTrials.gov Identifier: NCT01696422 https://clinicaltrials.gov/ct2/show/NCT01696422 Cited 14 October 2016.

27. ClinicalTrials.gov Identifier: NCT02406729 https://clinicaltrials.gov/ct2/show/NCT02406729 Cited 14 October 2016.